Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Jan 18, 2007

Premium
Title: Methods and Compositions for the Inhibition of Stat5 in Prostate Cancer Cells
 
Number: 20070010468
 
Filed: April 23, 2004 PCT Filed: April 23, 2004
 
Inventor: Marja Nevalainen, Georgetown University
 
The invention “relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells,” the patent application’s abstract states.
 

 
Title: Micellar Systems
 
Number: 20070010004
 
Filed: June 30, 2006
 
Lead Inventor: Sean Monahan, Mirus Bio
 
According to its abstract, the patent application covers “methods … for modifying nucleic acids to facilitate delivery of the nucleic acids to cells. Compounds which interact with or modify nucleic acids are interacted with the nucleic acids within reverse micelles,” the abstract adds.
 

 
Title: Methods and Compositions for Inhibiting Tumorigenesis
 
Number: 20070009530
 
Filed: April 20, 2006
 
Lead Inventor: Ariel Ruiz Altaba, University of Geneva Medical School
 
The invention, the patent application’s abstract states, “relates to compounds, small interfering RNAs, and compositions and methods of inhibiting tumorigenesis and methods of inhibiting tumor cell growth and proliferation using agents that inhibit the hedgehog and GLI signaling pathway, including agents that inhibit GLI synthesis and/or function. The … invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of melanomas,” the abstract states. “Methods of treating cancer, including melanoma, are also provided using small organic compounds, siRNAs, and blocking antibodies that inhibit or block the SHH/GLI pathway. In addition, the use of agents that inhibit other signaling pathways is contemplated for use as second agents to be used in conjunction with the inhibitors of the GLI pathway.”

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.